<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5554">
  <stage>Registered</stage>
  <submitdate>28/04/2010</submitdate>
  <approvaldate>28/04/2010</approvaldate>
  <nctid>NCT01117792</nctid>
  <trial_identification>
    <studytitle>Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation</studytitle>
    <scientifictitle>Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DN-01040</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>ACC/AHA/NASPE Class 1, IIa or IIb Indications</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - subcutaneous implantable defibrillator (S-ICD) system

Experimental: S-ICD System - 


Treatment: devices: subcutaneous implantable defibrillator (S-ICD) system
implantable defibrillator system

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Conversion of induced ventricular fibrillation - Data was reported at 30 days and 6 months</outcome>
      <timepoint>testing done during the implant procedure</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Replacement of an existing implanted transvenous ICD system

          -  Class I, Class IIa, or Class IIb ACC/AHA/HRS indications for patients without an
             existing transvenous ICD system

          -  Age is &gt;= 18 years

          -  Appropriate pre-operative ECG as measured with a specially developed template</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects unable or unwilling to provide informed consent

          -  Any condition which precludes the subject's ability to comply with the study
             requirements

          -  Females who are pregnant or lactating and pre-menopausal women who are unwilling to
             use adequate birth control for the duration of the study

          -  Participation in another investigational device trial at any time during the conduct
             of the S-ICD system trial without written consent from the sponsor.

          -  Patients with a serious medical condition and life expectancy of less than one year.

          -  Patients with documented spontaneous and frequently recurring VT that is reliably
             terminated with anti-tachycardia pacing

          -  Patients with existing epicardial patches or subcutaneous electrodes in the left
             thoracic quadrant

          -  Patients with impaired kidney function as measured by a Cockcroft-Gault Glomerular
             Filtration Rate (GFR) with a GFR &lt;= 29.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>55</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Donato Milanese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dudley</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective is to evaluate the S-ICD system's ability to identify and terminate
      induced ventricular fibrillation in patients during the implant procedure. The safety and
      performance of the S-ICD system will also be assessed throughout the patient follow-up
      period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01117792</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen O'Connor, PhD, Hon FRCP</name>
      <address>Boston Scientific Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>